Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Perrigo, a developer, manufacturer and distributor of OTC and generic prescription pharmaceuticals, infant formulas, nutritional products, APIs and pharmaceutical and medical diagnostics, has agreed to settle its Hatch-Waxman litigation related to the Rogaine (Minoxidil) foam brought by Stiefel Research Australia, a GSK company.
Subscribe to our email newsletter
Rogaine (Minoxidil) foam is used to regrow hair on the top of the scalp.
The settlement terms indicate that Perrigo can now launch a generic version of Men’s Rogaine Foam on 1 March 2012 or earlier in the US under certain circumstances.
Perrigo chairman and CEO Joseph Papa said this was another example of Perrigo’s commitment to bring quality, affordable healthcare products to market.